Reliability of Core Needle Biopsy in Evaluating Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2, and Ki-67 Status

키워드

참고문헌 (28)

1. Perou CM, "Molecular portraits of human breast tumours", Nature, 406, pp.747~752 (2000)
2. Sørlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)
3. Goldhirsch A, "Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
4. de Azambuja E, "Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients", Br J Cancer, 96, pp.1504~1513 (2007)
5. Jones RL, "The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer", Breast Cancer Res Treat, 116, pp.53~68 (2009)
6. Goldhirsch A, "Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
7. Guarneri V, "Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management", Oncologist, 13, pp.838~844 (2008)
8. Lindström LS, "Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression", J Clin Oncol, 30, pp.2601~2608 (2012)
9. Lorgis V, "Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour", Breast, 20, pp.284~287 (2011)
10. Arnedos M, "Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)", Ann Oncol, 20, pp.1948~1952 (2009)
11. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
12. Dowsett M, "Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group", J Natl Cancer Inst, 103, pp.1656~1664 (2011)
13. Park SY, "The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer", Am J Surg, 197, pp.266~269 (2009)
14. Chen X, "Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer", BMC Cancer, 13, pp.390~ (2013)
15. Zidan A, "Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma", J Clin Pathol, 50, pp.27~29 (1997)
16. Mann GB, "Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer", J Clin Oncol, 23, pp.5148~5154 (2005)
17. Burge CN, "Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?", Breast, 15, pp.167~172 (2006)
18. Tagliabue E, "Role of HER2 in wound-induced breast carcinoma proliferation", Lancet, 362, pp.527~533 (2003)
19. Gandini S, "Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials", Ann Oncol, 25, pp.618~623 (2014)
20. Dekker TJ, "Reliability of core needle biopsy for determining ER and HER2 status in breast cancer", Ann Oncol, 24, pp.931~937 (2013)
21. Usami S, "Reliability of prognostic factors in breast carcinoma determined by core needle biopsy", Jpn J Clin Oncol, 37, pp.250~255 (2007)
22. Douglas-Jones AG, "Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma", J Clin Pathol, 54, pp.951~955 (2001)
23. Chen X, "Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis", Breast Cancer Res Treat, 134, pp.957~967 (2012)
24. Pathmanathan N, "Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing", Breast, 21, pp.724~729 (2012)
25. Werner M, "Effect of formalin tissue fixation and processing on immunohistochemistry", Am J Surg Pathol, 24, pp.1016~1019 (2000)
26. Peto R, "Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials", Lancet, 379, pp.432~444 (2012)
27. Davies C, "Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials", Lancet, 378, pp.771~784 (2011)
28. Untch M, "Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups", J Clin Oncol, 29, pp.3351~3357 (2011)

관련 논문AI추천